Why GW Pharmaceuticals (GWPH) Stock Is Up Today

NEW YORK (TheStreet) -- GW Pharmaceuticals (GWPH) shares are up 3% to $64 on Monday following the announcement that its Sativex drug treatment had received a "fast track" designation from regulators at the Food and Drug Administration.

The fast track program is designed to facilitate the development of drugs intended to treat life threatening diseases. 

Sativex, a cannaboid based treatments that is comprised of CBD (cannabidiol) and THC, is designed to treat pain associated with advanced stages of cancer. It is currently in Phase 3 clinical trials.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. 

GWPH Chart

GWPH data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months.Learn more.

More from Markets

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%